Latest News Gedea Biotech appoints Julie Waras Brogren as new CEO to lead the company into its commercialization phaseGedea Biotech today announces a planned CEO transition. After close to ten years as CEO, Annette Säfholm has decided to…27 January 2026Gedea Biotech announce start of the clinical study BV2025 following CE marking of pHyph —first patients enrolledGedea Biotech today announced that the clinical trial BV2025 has started, following approval from the Swedish Medical…22 January 2026Gedea Biotech strengthens its Board with extensive commercial expertise to support next phaseLund, Sweden – November 18, 2025 Gedea Biotech, an innovative Swedish life science company in women’s health, today…18 November 2025New insights into the vaginal microbiome: Emilia Lahtinen’s industrial PhD journeyAt the intersection of academic research and biotech innovation, Emilia Lahtinen is pursuing her industrial PhD as a…6 November 2025Gedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial VaginosisGedea Biotech Announces CE-Marking for pHyph: A Novel Antibiotic-Free Treatment for Bacterial Vaginosis 2 September 2025PRESS RELEASE Gedea Biotech Receives US Patent for Preventing Preterm BirthGedea Biotech announced today that the United States Patent and Trademark Office (USPTO) has granted the company’s…27 March 2025Gedea Biotech Reports Significant Results in Study for the Treatment of Bacterial Vaginosis12 March 2025 Press KitClick to download logos and images.
